Guideline #	Guideline Name	Type of Change	Brief Description of Guideline Change	Reason for Changes
ECG 3029	Zynyz (retifanlimab-dlwr)	No clinical change	Updated references	Annual Review
ECG 3135	Zolinza (vorinostat)	No clinical change	Updated references	Annual Review
ECG 3136	Istodax (romidepsin)	No clinical change	Updated references	Annual Review
ECG 3137	Ixempra (ixabepilone)	No clinical change	Updated references	Annual Review
ECG 3138	Vitrakvi (larotrectinib)	No clinical change	1) Added oral solution formulation details to exclusion criteria 2) Updated references	Annual Review
ECG 3139	Xospata (gilteritinib)	No clinical change	Updated references	Annual Review
ECG 3140	Cablivi (caplacizumab-yhdp)	No clinical change	Updated references	Annual Review
ECG 3141	Daurismo (glasdegib)	No clinical change	1) Updated maximum dosage form quantities in exclusion criteria 2) Updated references	Annual Review
ECG 3142	Ayvakit (avapritinib)	No clinical change	Updated references	Annual Review
ECG 3143	Gamifant (emapalumab-lzsg)	No clinical change	Updated references	Annual Review
ECG 3144	Sylvant (siltuximab)	No clinical change	Updated references	Annual Review
ECG 3145	Unituxin (dinutuximab)	No clinical change	Updated references	Annual Review
ECG 3147	Pemazyre (pemigatinib)	No clinical change	Updated references	Annual Review
ECG 3149	Tivdak (tisotumab vedotin-tftv)	No clinical change	Updated references	Annual Review
ECG 3152	Ibtrozi (taletrectinib)	No clinical change	Updated references	Annual Review
EMOD.0001	Medical Oncology Drug List Policy	No clinical change	No changes	Annual Review
ECG 3159	Keytruda and Keytruda Qlex (pembrolizumab IV/SC)	Positive	1) On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. 2) On June 24, 2026, the Food and Drug Administration approved sacituzumab govitecan-hziy in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the first-line treatment of adults with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA-authorized test. 1) Updated RCC indication to include use with Welireg (belzutifan) 2) TNBC indication was added in March 2026 3) Updated references	New FDA Drug/Indication
ECG 3052	Welireg (belzutifan)	Positive	On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. 1) Updated RCC indication to include use with Keytruda or Keytruda Qlex (pembrolizumab IV/SC) 2) Updated contraindications/warnings section 3) Updated exclusion criteria 4) Updated references	New FDA Drug/Indication
ECG 3249	Truqap (capivasertib)	Positive	On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test. 1) Added prostate cancer to indication section 2) Updated exclusion criteria 3) Updated references	New FDA Drug/Indication
ECG 3191	Abirtega/Yonsa/Zytiga (abiraterone acetate)	Positive	On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test. 1) Updated indication section 2) Updated references	New FDA Drug/Indication

ECG 3114	Ibrance (palbociclib)	Positive	On June 24, 2026, the Food and Drug Administration approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment. 1) Updated indication section 2) Updated references	New FDA Drug/Indication
ECG 3073	Trastuzumab Products, Pertuzumab Products, and Pl	Positive	On June 24, 2026, the Food and Drug Administration approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment. 1) Updated indication section 2) Updated exclusion criteria 3) Updated references	New FDA Drug/Indication
ECG 3261	Trodelvy (sacituzumab govitecan-hziy)	Positive	On June 24, 2026, the Food and Drug Administration approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for two indications in adults with triple-negative breast cancer (TNBC). The first indication, supported by ASCENT-03, is for sacituzumab govitecan-hziy as a single agent for the first-line treatment of adults with unresectable locally advanced or metastatic TNBC who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. The second indication, supported by ASCENT-04/KEYNOTE D-19, is for sacituzumab govitecan-hziy in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the first-line treatment of adults with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA-authorized test. 1) Both indications were added in March 2026 2) Updated references	New FDA Drug/Indication
ECG 3267	Lifyorli (relacorilant)	Negative	1) Changed to an LVR the new indication for ovarian cancer with use in combination with Abraxane (nab-paclitaxel) for the treatment of members with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab - Increased financial toxicity for a modest survival benefit compared to single-agent chemotherapy 2) Updated references	Other
ECG 3000	Abraxane (nab-paclitaxel)	Negative	1) Policy already states Abraxane (nab-paclitaxel) as an LVR for ovarian cancer 2) Updated references	Other
ECG 3018	Opdivo and Opdivo Qvantig (nivolumab IV/SC)	Positive	1) Updated NSCLC indication to include use in combination with ipilimumab ± chemotherapy in metastatic NSCLC (both squamous and non-squamous) that is positive for the KEAP1 mutation, regardless of PD-L1 expression 2) Updated references	Other
ECG 3155	Yervoy (ipilimumab)	Positive	1) Updated NSCLC indication to include use in combination with nivolumab ± chemotherapy in metastatic NSCLC (both squamous and non-squamous) that is positive for the KEAP1 mutation, regardless of PD-L1 expression 2) Updated references	Other
ECG 3026	Yondelis (trabectedin)	Positive	1) Added new branded product “Evdi” to all relevant sections 2) Updated references	Other
ECG 3039	Generic Drugs	Positive	Added “Favlyxa (fluorouracil)”, “Avopef (etoposide)”, “Boruzu (bortezomib)”, and “Vykoura (leucovorin)” to the drug list in Attachment A	Other
ECG 3109	Intravenous Immune Globulin (IG)	Positive	1) Added additional IVIG product “Qivigy” to all relevant sections 2) Updated HCPC codes 3) Updated references	Other
ECG 3110	Sprycel (dasatinib)	Positive	1) Added new branded product “Phyrago” to all relevant sections 2) Updated references	Other
ECG 3150	Epkinly (epcoritamab-bysp)	Positive	1) Per NCCN, updated DLBCL indication for use in combination with GEMOX after failure of at least one line of systemic therapy 2) Updated references	Other
ECG 3035	Enhertu (fam-trastuzumab deruxtecan-nxki)	Positive	Per NCCN, updated solid tumor indication to allow use in HER2-positive tumors with FISH+, or IHC 3 + or 2+	Other

ECG 3106	Myeloid Growth Factors (MGFs)	Positive	1) Added additional MGF products “Armlupeg” and “Ennumo” to all relevant sections 2) Updated HCPC codes 3) Updated references	Other